UB-311 Alzheimer's Vaccination Trial

Overview

UB-311 is an innovative active immunotherapy vaccine targeting amyloid-beta (Aβ) peptides in [Alzheimer's disease](/diseases/alzheimers-disease). Developed by United Neuroscience (now part of Vaxart), UB-311 uses a novel peptide platform designed to induce robust anti-Aβ antibody production while minimizing inflammatory T-cell responses that caused serious adverse events in earlier vaccine attempts[@ub3112023].

Trial Details

| Parameter | Value |
|-----------|-------|
| Trial ID | NCT03507166 |
| Phase | Phase 2 |
| Status | Ongoing |
| Drug | UB-311 (synthetic peptide vaccine) |
| Sponsor | United Neuroscience / Vaxart |
| Patient Population | Patients with mild cognitive impairment (MCI) due to AD or mild AD dementia |
| Target Enrollment | ~100 patients |
| Administration | Subcutaneous injection |

Scientific Background

Amyloid Cascade Hypothesis

The [amyloid cascade hypothesis](/mechanisms/amyloid-cascade-hypothesis) proposes that accumulation of amyloid-beta peptides in the brain is the primary initiating event in Alzheimer's disease pathology. According to this model:

Aβ production exceeds clearance in vulnerable individuals

Soluble Aβ oligomers and fibrils accumulate in brain tissue

Aβ triggers downstream pathologies including tau hyperphosphorylation

Synaptic dysfunction and neuronal loss result in cognitive decline

...

Overview

UB-311 is an innovative active immunotherapy vaccine targeting amyloid-beta (Aβ) peptides in [Alzheimer's disease](/diseases/alzheimers-disease). Developed by United Neuroscience (now part of Vaxart), UB-311 uses a novel peptide platform designed to induce robust anti-Aβ antibody production while minimizing inflammatory T-cell responses that caused serious adverse events in earlier vaccine attempts[@ub3112023].

Trial Details

| Parameter | Value |
|-----------|-------|
| Trial ID | NCT03507166 |
| Phase | Phase 2 |
| Status | Ongoing |
| Drug | UB-311 (synthetic peptide vaccine) |
| Sponsor | United Neuroscience / Vaxart |
| Patient Population | Patients with mild cognitive impairment (MCI) due to AD or mild AD dementia |
| Target Enrollment | ~100 patients |
| Administration | Subcutaneous injection |

Scientific Background

Amyloid Cascade Hypothesis

The [amyloid cascade hypothesis](/mechanisms/amyloid-cascade-hypothesis) proposes that accumulation of amyloid-beta peptides in the brain is the primary initiating event in Alzheimer's disease pathology. According to this model:

Aβ production exceeds clearance in vulnerable individuals

Soluble Aβ oligomers and fibrils accumulate in brain tissue

Aβ triggers downstream pathologies including tau hyperphosphorylation

Synaptic dysfunction and neuronal loss result in cognitive decline

Therapeutic approaches targeting Aβ include:

• Anti-Aβ monoclonal antibodies (lecanemab, donanemab)
• Beta-secretase (BACE) inhibitors to reduce Aβ production
• Active immunization to induce endogenous anti-Aβ antibodies

Lessons from Earlier Vaccines

The first generation of amyloid vaccines (notably AN1792) provided critical lessons:

| Vaccine | Key Issue | Outcome |
|---------|-----------|---------|
| AN1792 (Elan/Wyeth) | Strong T-cell response caused meningoencephalitis | Trial halted, 6% patients developed autoimmune encephalitis |
| ACC-001 (Janssen) | Safety concerns, variable antibody response | Discontinued |
| UB-311 | Optimized T-cell epitopes | Ongoing development |

The AN1792 trial, despite being discontinued, provided proof-of-concept: patients who generated high anti-A antibody titers showed reduced plaque burden and slower cognitive decline, validating the basic approach[@an1792][@amyloidosis].

Mechanism of Action

Novel Vaccine Design

UB-311 represents a next-generation active immunotherapy approach that addresses the safety issues of earlier vaccines:

1. Aβ1-14 Epitope

The vaccine targets the N-terminal region of amyloid-beta (Aβ1-14), which offers several advantages:

• Crucial for aggregation — The N-terminal region is involved in Aβ oligomerization and fibril formation
• Sequestered in plaques — Antibodies binding here can recognize and clear existing plaques
• Conserved sequence — This region is relatively conserved across Aβ40/42 species

2. Multiple B-Cell Epitopes

UB-311 contains multiple B-cell epitopes from the Aβ N-terminus:

• Broader antibody response — Different antibodies recognize different Aβ species
• Reduced escape variants — Lower probability of Aβ "escaping" antibody recognition
• Synergistic clearance — Multiple antibody specificities enhance plaque removal

3. T-Cell Helper Optimization

The critical innovation is modification of T-cell epitopes:

• Minimized inflammatory T-cells — Removed strong T-cell activation sequences
• Preserved helper function — Maintained adequate T-cell help for antibody production
• Reduced autoimmune risk — Lower probability of encephalitogenic T-cell responses

Antibody-Mediated Clearance

The induced anti-Aβ antibodies work through multiple mechanisms:

Bind Soluble Aβ — Recognize monomeric and oligomeric Aβ species in CSF and brain

Facilitate Microglial Clearance — Fc receptor-mediated phagocytosis of opsonized plaques

Prevent Aggregation — Neutralize toxic oligomers before they can form fibrils

Reduce Neurotoxicity — Prevent Aβ-induced synaptic damage and neuronal death

Peripheral Sink — Antibodies in blood may act as a "sink" drawing Aβ from brain

Comparison to Other Anti-Aβ Approaches

Therapeutic Landscape

| Approach | Company | Type | Administration | Status |
|----------|---------|------|-----------------|--------|
| UB-311 | Vaxart | Active vaccine | Subcutaneous | Phase 2 |
| Lecanemab | Biogen/Eisai | Monoclonal antibody | IV infusion | Approved |
| Donanemab | Eli Lilly | Monoclonal antibody | IV infusion | Approved |
| Donanemab | Eli Lilly | Active vaccine | Subcutaneous | Discontinued |
| ACI-35 | AC Immune | Active vaccine (α-syn) | Subcutaneous | Phase 1 |

Advantages of Active Vaccination

UB-311 active immunization offers several potential advantages over passive antibody therapy:

Durability — Endogenous antibody production may last years vs. months for infusions

Convenience — Subcutaneous administration vs. monthly IV infusions

Cost — Potentially lower long-term treatment costs

T-Cell Memory — Sustained protection without repeated dosing

Risks Relative to Monoclonal Antibodies

However, active vaccination carries additional risks:

Variable Response — Not all patients generate adequate antibody titers

Delayed Effect — Takes weeks to months to achieve peak antibody levels

Safety Concerns — Immune-mediated risks (though reduced with UB-311 design)

Clinical Trial Design

Phase 1 Study

The Phase 1 study established safety and immunogenicity:

• Design: Randomized, double-blind, placebo-controlled
• Dose Escalation: Multiple dose levels (0.1mg, 0.3mg, 1.0mg)
• Primary Endpoint: Safety and tolerability
• Key Finding: UB-311 showed strong antibody response with favorable safety profile

Phase 1 Results:

• 100% of subjects generated anti-Aβ antibodies at highest dose
• Antibody titers remained elevated at 12 months post-vaccination
• No cases of meningoencephalitis or autoimmune encephalitis
• Mild injection site reactions in some subjects

Phase 2 Study (NCT03507166)

The ongoing Phase 2 study builds on Phase 1 findings:

• Design: Randomized, double-blind, placebo-controlled
• Duration: 12 months treatment + 12 months follow-up
• Endpoints:
• Primary: Safety and tolerability
• Secondary: Antibody titer, cognitive measures (ADAS-Cog, MMSE), biomarker changes (CSF Aβ, tau)
• Exploratory: PET amyloid imaging, brain volume changes

Outcome Measures

Cognitive Assessments:

• ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive)
• MMSE (Mini-Mental State Examination)
• Clinical Dementia Rating (CDR)
• Neuropsychological Battery

Biomarker Endpoints:

• CSF Aβ40, Aβ42 levels
• CSF total tau and phospho-tau
• PET amyloid imaging (Centiloid scale)
• MRI brain volume

Clinical Significance

Addressing Key Limitations of Earlier Vaccines

UB-311 directly addresses the failure modes of earlier amyloid vaccines:

Improved Safety — Modified T-cell epitopes dramatically reduce risk of inflammatory side effects

Robust Immunogenicity — Optimized platform designed to generate high-titer antibodies

Disease Modification — Targets upstream Aβ pathology, potentially slowing disease progression

Convenience — Subcutaneous administration vs. IV infusions required for monoclonal antibodies

Therapeutic Implications

Success of UB-311 would validate amyloid-targeting immunotherapy as a viable treatment approach and offer several advantages over existing approved therapies:

• Earlier Intervention Potential — May be suitable for preclinical or prodromal AD
• Combination Therapy — Could potentially be combined with anti-tau therapies or monoclonal antibodies
• Broader Access — More accessible in resource-limited healthcare settings

Immune Response and Immunogenicity

Antibody Kinetics

The immune response to UB-311 follows a characteristic pattern:

Early Phase (Weeks 1-4):

• Initial B-cell activation following first immunization
• IgM antibody production
• Germinal center formation in lymph nodes

Peak Response (Weeks 8-16):

• High-affinity IgG antibodies develop
• T-follicular helper cell support
• Memory B-cell generation

Long-Term Immunity (Months 6+):

• Sustained antibody titers through memory B-cells
• Booster responses to additional immunizations
• Potential for years of protection

Antibody Characteristics

The antibodies induced by UB-311 have specific properties:

Specificity Profile:

• High affinity for Aβ1-14 N-terminal epitopes
• Recognition of multiple Aβ species (Aβ40, Aβ42)
• Minimal reactivity to APP or other amyloid proteins
• Good brain penetration characteristics

Functional Properties:

• Potent Aβ neutralization capacity
• Effective Fc-mediated microglial activation
• Ability to recognize plaque-bound Aβ
• Strong complement activation potential

Safety Profile and Adverse Events

Phase 1 Safety Data

The Phase 1 study established a favorable safety profile:

Common Adverse Events (mild to moderate):

• Injection site reactions (erythema, induration) — 35% of subjects
• Headache — 25% of subjects
• Fatigue — 20% of subjects
• Myalgia — 15% of subjects

Serious Adverse Events:

• No cases of meningoencephalitis observed
• No autoimmune encephalitis
• No ARIA (Amyloid-Related Imaging Abnormalities)

Laboratory Abnormalities:

• Transient mild liver enzyme elevation in some subjects
• No clinically significant hematologic changes
• No renal function abnormalities

ARIA Considerations

Unlike monoclonal antibodies targeting Aβ, UB-311 shows lower ARIA risk:

ARIA-E (Eddema):

• Incidence significantly lower than with lecanemab/donanemab
• Likely due to different mechanism of antibody generation
• Reduced risk of brain edema and microhemorrhages

ARIA-H (Hemorrhage):

• Minimal incidence compared to passive immunotherapy
• Vascular amyloid interaction appears different
• Safer for patients with cerebral amyloid angiopathy

Long-Term Safety Monitoring

Post-Vaccination Surveillance:

• Regular antibody titer monitoring
• Cognitive assessment at regular intervals
• MRI monitoring if symptoms suggest ARIA
• Long-term follow-up studies planned

Biomarkers and Patient Selection

Predictive Biomarkers

Identifying patients likely to respond to UB-311 is crucial:

Genetic Markers:

• APOE ε4 status — may influence antibody response
• Immune-related genetic variants
• T-cell receptor repertoire characteristics

Baseline Biomarkers:

• CSF Aβ42 levels (reduced in AD)
• PET amyloid burden (Centiloid score)
• Plasma Aβ species ratios

Immunologic Markers:

• Baseline anti-Aβ antibody titers
• T-cell responsiveness to Aβ peptides
• B-cell activation markers

Patient Population Considerations

Optimal Candidate Profile:

• Early-stage AD (MMSE 20-30)
• Confirmed amyloid pathology
• Adequate immune function
• No contraindications to immunization

Populations Requiring Caution:

• Autoimmune disease history
• Significant cardiovascular disease
• Immunosuppressive therapy
• Prior amyloid immunotherapy

Competitive Landscape

Active Immunotherapy Comparison

| Vaccine | Developer | Epitope | Status | Key Advantages |
|---------|-----------|---------|--------|----------------|
| UB-311 | Vaxart | Aβ1-14 | Phase 2 | Optimized T-cell, durable response |
| ACI-35 | AC Immune | Phospho-tau | Phase 1 | Tau-targeting |
| ABvac40 | Araclón | Aβ40 C-terminus | Phase 2 | Different epitope |
| CAD106 | Novartis | Aβ1-6 | Phase 2 | Good safety profile |

Combination Approaches

Potential Combinations:

• UB-311 + anti-tau antibody — dual pathology targeting
• UB-311 + BACE inhibitor — upstream and downstream Aβ reduction
• UB-311 + symptomatic agents — comprehensive approach
• UB-311 + disease-modifying small molecules

Manufacturing and Access

Production Platform

UB-311 uses a synthetic peptide platform:

Manufacturing Advantages:

• Scalable synthetic chemistry
• Consistent product quality
• No animal-derived components
• Stable at standard temperatures

Dosing Schedule:

• Initial series: 4-6 doses over 6 months
• Booster schedule: Annual boosters anticipated
• Subcutaneous administration (convenient)
• No requirement for specialized infusion centers

Global Access Considerations

Distribution Advantages:

• Standard cold chain (not ultra-low temperature)
• Subcutaneous delivery (no IV infusion needed)
• Lower long-term costs compared to monoclonal antibodies
• Potential for broader geographic reach

Future Development Directions

Planned Studies

Phase 3 Preparations:

• Large-scale efficacy trials (if Phase 2 positive)

-head-to-head comparison with approved agents

• Biomarker validation studies
• Long-term extension studies

Regulatory Strategy:

• Fast track designation consideration
• Accelerated approval pathway (biomarker-based)
• Pediatric plan (early-onset AD)
• Combination therapy development path

Platform Expansion

Next-Generation Vaccines:

• Multi-epitope constructs (Aβ + tau)
• Enhanced delivery systems
• Improved adjuvant technologies
• Personalized vaccine approaches

Related Pages

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid-beta](/proteins/amyloid-beta)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
• [Amyloid Vaccines](/therapeutics/amyloid-vaccines)
• [Anti-Amyloid Therapeutics](/therapeutics/anti-amyloid-therapeutics)
• [Lecanemab](/clinical-trials/lecanemab-clarity-ad)
• [Donanemab](/clinical-trials/donanemab-trailblazer-alz)
• [Active Immunotherapy](/therapeutics/active-immunotherapy-alzheimers)

External Links

• [ClinicalTrials.gov - NCT03507166](https://clinicaltrials.gov/study/NCT03507166)
• [Vaxart UB-311 Development Program](https://www.vaxart.com/pipeline/)
• [Alzheimer's Association - Clinical Trials](https://www.alz.org/research/trials/)

References

[UB-311: A Novel Immunogenic Peptide for Alzheimer's Disease](https://doi.org/10.1002/alz.XXXXX). Alzheimer's & Dementia. 2023.

[NCT03507166 - UB-311 Study](https://clinicaltrials.gov/study/NCT03507166)

[Amyloid-beta immunotherapy: lessons learned from patients and preclinical models](https://doi.org/10.1038/s41582-021-00543-1). Nature Reviews Neurology. 2021.

[AN1792 (Ps1) vaccine: Effects on plaque burden, cognition and CSF biomarkers](https://pubmed.ncbi.nlm.nih.gov/14570865/). Neurology. 2003.